Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology

Cancer Cytopathology

Volumn 121, Issue 8, 2013, Pages 415-422

  Matsumoto, Shinji ^a   Nabeshima, Kazuki ^a   Kamei, Toshiaki ^b   Hiroshima, Kenzo ^c   Kawahara, Kunimitsu ^d   Hata, Sakae ^e   Marukawa, Katsuji ^f   Matsuno, Yoshihiro ^f   Taguchi, Kenichi ^g   Tsujimura, Tohru ^h  

^a FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^b Yamaguchi Grand Medical Center   (Japan)

^c Tokyo Women s Medical University   (Japan)

^d OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^e KAWASAKI MEDICAL SCHOOL   (Japan)

^f HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

9p21 homozygous deletion; Cytology; Fluorescence in situ hybridization; P16; Pleural mesothelioma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CELL; CELL STRUCTURE; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; CYTODIAGNOSIS; EFFUSION CYTOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HOMOZYGOSITY; HUMAN; HUMAN CELL; MALE; MESOTHELIUM CELL; MICROSCOPE; MULTINUCLEAR CELL; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; VIRTUAL MICROSCOPE;

9P21 HOMOZYGOUS DELETION; CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; P16; PLEURAL MESOTHELIOMA;

AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; CYTODIAGNOSIS; FEMALE; GENES, P16; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; USER-COMPUTER INTERFACE;

EID: 84880265119     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21269     Document Type: Article

References (20)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603. (Pubitemid 41434638)
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081-2090.
3. Senyigit A, Bayram H, Babayigit C, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration. 2000;67:615-622. (Pubitemid 32008887)
4. Chapman A, Mulrennan S, Ladd B, Muers MF. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax. 2008;63:435-439. (Pubitemid 351692353)
5. Savic S, Franco N, Grilli B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010;138:137-144.
6. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54:5547-5551.
7. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21:742-747. (Pubitemid 351744840)
8. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63:630-634.
9. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis. 2002;23:1127-1130. (Pubitemid 34814769)
10. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99:51-56. (Pubitemid 36267967)
11. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453:627-635.
12. Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Bocking A. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer. 2008;114:204-215. (Pubitemid 351969240)
13. Takeda M, Kasai T, Enomoto Y, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60:395-399.
14. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: International Agency for Research on Cancer Press; 2004.
15. Leong AS, Stevens MW, Mukherjee TM. Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation. Semin Diagn Pathol. 1992;9:141-150.
16. Stevens MW, Leong AS, Fazzalari NL, Dowling KD, Henderson DW. Cytopathology of malignant mesothelioma: A stepwise logistic regression analysis. Diagn Cytopathol. 1992;8:333-341.
17. Cakir E, Demirag F, Aydin M, Unsal E. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis. Diagn Cytopathol. 2009;37:4-10.
18. Sakuma N, Kamei T, Shibuta H, Okamura H. Characteristics of reactive mesothelia, plumonary adenocarcinoma, and malignant mesothelioma in pleural effusion, with special reference to the nucleus number. J Jpn Soc Clin Cytol. 2002;41:145-149.
19. Hamakawa S, Mori K, Kashiwazaki Y, et al. Molded mesothelial cells with hump-like cytoplasmic process in effusion cytology of malignant mesothelioma. J Jpn Soc Clin Cytol. 2003;42:10-16.
20. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993- 1000. (Pubitemid 26006540)